Selecting a Biologics CDMO
for Clinical Supply and Scale-Up

DECISION QUESTION Which CDMO should be appointed for Phase II drug-substance manufacturing, and what must be controlled now to preserve a credible commercial scale-up path?

Timing conflict Candidate A's earliest credible start would miss the clinical programme's required manufacturing window by approximately five months.

Scale-path uncertainty Candidate B could meet the clinical window, but future demand would require reserved expansion capacity or a controlled second-site strategy.

Evidence asymmetry Candidate C's rapid availability was attractive, yet several claims depended on group-level statements rather than site-specific operating evidence.

Critical-path reconstruction Map the sequence from data-room access and cell-bank transfer through engineering runs, analytical readiness, GMP manufacture, release and stability. Each candidate's stated timeline is tested against dependencies rather than accepted as a single date.

Site-level evidence separation Distinguish corporate network capabilities from the facility, suite, quality unit and team that would perform the client's work.

Transfer-friction analysis Identify process, analytical, material, documentation and equipment differences that could create rework or delay during technology transfer.

Capacity-window verification Compare announced capacity with credible slot availability, competing programme commitments, campaign structure and future reservation requirements.

Quality and governance fit Examine inspection history, quality systems, deviation and change-control expectations, information access, escalation routes and the proposed quality-agreement structure.

Scale-path stress test Test whether the clinical appointment remains viable if demand accelerates, a batch fails, the launch timing changes or a second site becomes necessary.

Pressure case 1 - clinical demand increases by 40% The candidate remains viable only if the client reserves an additional manufacturing window before completion of the first GMP batch. Without that reservation, future campaign timing becomes the dominant exposure.

Pressure case 2 - technology transfer slips by twelve weeks The clinical milestone can still be protected if analytical-method work begins in parallel and the client establishes a joint weekly issue-resolution forum. A longer delay would require escalation to the contingency candidate.

Pressure case 3 - commercial timing accelerates Candidate B would need to demonstrate a controlled scale or second-site route earlier than planned. The recommendation therefore requires a scale-path decision gate before pivotal development begins.

QUALIFY WITH CONDITIONS Advance Candidate B as the preferred Phase II manufacturing partner, subject to capacity reservation, site-specific quality confirmation, agreed information access and an explicit commercial scale-path gate.

Decision dossier A concise appointment case showing the preferred candidate, conditions, rejected alternatives and unresolved evidence.

Critical-path model A dependency-led transfer and manufacturing timeline that separates stated dates from credible execution dates.

Candidate evidence matrix Site-level comparison covering capability, quality, capacity, transfer, governance, subcontracting and scale readiness.

Stress-test and control plan Pressure cases, decision breakpoints, escalation triggers and conditions for qualification or contingency activation.

LET'S DISCUSS YOUR MANUFACTURING-PARTNER DECISION August Research can help reconstruct the evidence behind a CDMO shortlist, identify the conditions that determine suitability and prepare the client for focused technical, quality and commercial diligence.